Drug intelligence / Profile preview

BR005

Development stage: Preclinical
Lead developer: Brise Pharmaceuticals

Overview

BR005 is a clinical-stage drug candidate developed by Brise Pharmaceuticals, a biopharmaceutical company based in Shanghai, China. It is being developed for the treatment of migraine. The drug's development is based on Brise Pharmaceuticals' Trigeminovascular System (TVS) and Dorsal Root Ganglion (DRG) biology-based drug development platforms, which are focused on innovative treatments for acute and chronic pain.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on BR005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR005.

Explore the full profile